Management of metastatic renal cell carcinoma has been enriched by the advent of new therapeutic compounds. The approval of new combination strategies between targeted agents and immune-checkpoint inhibitors as well as the administration of combinations between immune-checkpoint inhibitors has clearly demonstrated significant improvement toward patients' prognosis and other clinical outcomes. Due to the availability of different treatments, the choice between them may be a difficult issue in our clinical practice. We have summarized current knowledge about available treatments focusing on criteria, which may help clinicians to make decisions.
Keywords: atezolizumab; avelumab; combination strategies; immune-checkpoint inhibitors; immunotherapy; ipilimumab; metastatic renal cell; nivolumab; pembrolizumab; renal cell carcinoma.